Background: Secreted frizzled-related protein 1 (SFRP1) functions as a Wnt antagonist to repress the proliferation and migration of epithelial ovarian cancer cells. Recent research has shown that SFRP1 was reduced in the subcutaneous abdominal adipose stem cells isolated from patients with polycystic ovarian syndrome (PCOS). Regardless, the regulatory role and mechanism of SFRP1 in the proliferation and migration of granulosa cells during development of PCOS are scarce. Methods: SFRP1 expression was analyzed in plasma samples from patients with PCOS or immortalized human granulosa cells (KGN). Cell counting kit-8 (CCK-8) and colony formation assays were used to analyze the cell viability and proliferation of KGN, respectively. Cell apoptosis was analyzed by flow cytometry, and migration was detected by transwell. Results: SFRP1 expression was lower in plasma samples isolated from patients with PCOS than the healthy control. Immortalized human granulosa cells (KGN) also showed decreased SFRP1 expression compared to normal ovarian epithelial IOSE80 cells. pcDNA-mediated over-expression of SFRP1 reduced the cell viability and proliferation of KGN via cell counting kit-8 (CCK-8) and colony formation assays, respectively. Flow cytometry, analysis showed that the cell apoptosis of KGN was promoted by SFRP1. Ectopic expression of SFRP1 retarded cell migration with down-regulation of MMP2, MMP9, and vimentin. JNK phosphorylation was reduced in KGN with SFRP1 over-expression. Conclusion: SFRP1 contributed to the suppression of granulosa cell proliferation and migration through inhibition of JNK activation, providing a promising molecular target for PCOS.
Polycystic ovary syndrome (PCOS) is a disease with the highest incidence of endocrine disorders in reproductive-age women, and is the most common cause of poor fertility [1]. The most common characteristics of PCOS are excessive androgen secretion, low ovulation, polycystic ovary, sterility and metabolic dysfunction, and so on [2]. Genetic basis and environmental factors are considered as the main etiology of PCOS [3]. However, the exact pathogenesis of PCOS has not been fully understood and remains to be clarified.
Granulosa cells that provide growth regulators and nutrients to the oocyte are the important cellular components of the ovary, and the normal proliferation of granulosa cells is mainly involved in the physiological process of transition from primitive follicles to mature follicles [4]. However, granulosa cells have a higher proliferative rate in the ovaries of PCOS patients than that of healthy persons [5], and the increased granulosa cell proliferation is associated with abnormal folliculogenesis and ovulation in PCOS [5]. Silence of lncRNA UCA1 suppressed human granulosa-like tumor cell proliferation, and ameliorated pathological characteristics, including ovary structural damage and granule cell layers, of mice with PCOS [6]. Therefore, the inhibition of excessive proliferation of granulosa cell is one of the therapeutic strategies for the treatment of PCOS.
Proliferation of mouse granulosa cells is regulated by Wnt2/beta-catenin [7]. The
Wnts interact with Frizzled receptors to modulate ovarian steroidogenesis,
luteogenesis and normal folliculogenesis [8]. Activation of Wnt pathway was
related to the hallmarks of PCOS, including estrogen deficiency and insulin
resistance [8]. Secreted frizzled-related protein 1 (SFRP1) belongs to SFRPs
family, that function as the extracellular regulators of Wnt pathway, competes
with the Frizzled receptors for Wnt binding and participates in tumorigenesis [9]. SFRP1 has been shown to promote colorectal cancer cell apoptosis and repress
cell proliferation and metastasis [10]. SFRP1 suppressed Wnt/
In this study, the expression of SFRP1 in plasma samples of patients with PCOS was firstly analyzed, which indicated the diagnostic or prognostic roles o SFRP1 in the progression of PCOS. The effects and mechanism of SFRP1 on KGNcell proliferation and migration were then assessed, which could provide a promising molecular target for PCOS.
The outpatients and inpatients with PCOS (N = 15) and qualified non-PCOS patients (N = 15) with written informed consents were recruited at endocrinology and gynecology department of Hwa Mei Hospital, University of Chinese Academy of Sciences between 2017 and 2020. The local research was approved by the Hwa Mei Hospital, University of Chinese Academy of Sciences, University of Chinese Academy of Sciences and in accordance with 1964 Helsinki Declaration. The blood samples were from volunteers, and then centrifuged at 1200 g for 10 minutes to collect the plasma samples.
Human granulosa-like tumor cell line (KGN) and normal ovarian epithelial IOSE80
cells were purchased from the Cell Bank of the Chinese Academy of Science
(Shanghai, China). KGN was incubated in DMEM/F-12 medium with 10% fetal bovine
serum, 0.1 mg/mL streptomycin sulfate and 100 U/mL penicillin G (Hyclone, South
Logan, UT, USA) at a 37
RNAs were isolated from blood samples, KGN and IOSE80 cells via Trizol (TaKaRa,
Shiga, Japan). RNA was reverse-transcribed into cDNA, and qRT-PCR analysis was
assessed by Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA,
USA), and GAPDH was used as the endogenous control. The conditions were shown as:
94
ID | Sequences (5′-3′) |
GAPDH F | AGGTCGGTGTGAACGGATTTG |
GAPDH R | TGTAGACCATGTAGTTGAGGTC |
SFRP1 F | GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT |
SFRP1 R | CTCAACCTACAATCAAAAACAACACAAACA |
The pcDNA3.1-OSR1 was constructed by RiboBio (Guangzhou, China). KGN cells were
plated in the 96-well plates, and transfected with pcDNA3.1-SFRP1 or pcDNA vector
(300
The plasma samples, KGN and IOSE80 cells were lysed with RIPA Lysis and
Extraction Buffer (Thermo Fisher Scientific). The protein concentration of
lysates was calculated by acid protein kit (Thermo Fisher Scientific). The
lysates (30
KGN cells were plated in the 96-well plates for 24, 48, 72 or 96 hours, and then
incubated with 10
KGN cells in 100
KGN cells were harvested following centrifugation at 1000 g for 5 minutes. Cells
were then resuspended in 100
Data were expressed as mean
To determine the expression level of SFRP1 in patients with PCOS, the plasma samples collected from PCOS patients and non-PCOS patients (healthy controls) were used for the measurement of SFRP1 expression. The mRNA expression of SFRP1 was downregulated in PCOS patients as compared to that in healthy controls (Fig. 1A). In KGN cell, the lower expression of SFRP1 was showed as compared to that in IOSE80 cells (Fig. 1B,C), suggesting the potentially regulatory role of SFRP1 in the progression of PCOS.
Downregulation of SFRP1 in patients with PCOS.(A) SFRP1 was downregulated in the plasma samples from PCOS patients compared to
qualified non-PCOS patients (healthy controls) by qRT-PCR.
(B) The mRNA expression of SFRP1 was downregulated in KGN cells compared to that
in IOSE80 cells by qRT-PCR.
(C) The protein expression of SFRP1 was downregulated in KGN cells compared to
that in IOSE80 cells by western blot. ** p
To further explore the mechanism underlying the role of SFRP1 in the progression of PCOS, KGN cells was transfected with pcDNA vector for the over-expression of SFRP1. The protein expression of SFRP1 was higher in KGN cells transfected with pcDNA-SFRP1 than the control or pcDNA vector, indicating the successful transfection efficiency (Fig. 2A). The functional results showed that the ectopic expression of SFRP1 reduced KGN cell viability (Fig. 2B), and decreased cell colony formation (Fig. 2C), demonstrating the anti-proliferative effect of SFRP1 on the granulosa cells.
SFRP1 decreased KGN cell proliferation and colony formation.(A) Protein expression of SFRP1 was increased in KGN cells that transfected with
pcDNA-SFRP1 by western blot.
(B) Ectopic expression of SFRP1 reduced KGN cell viability by CCK-8.
(C) Ectopic expression of SFRP1 decreased KGN cell proliferation by colony
formation assay. ** p
The ectopic expression of SFRP1 significantly promoted KGN cell apoptosis compared to the control vector group (Fig. 3A). Besides, compared to the control vector group, transfection with pcDNA-SFRP1 down-regulated the protein expression of Bcl-2 (Fig. 3B), and up-regulated Bax and cleaved caspase-3 in KGN cells (Fig. 3B). These results indicated the pro-apoptotic effect of SFRP1 on the granulosa cells.
SFRP1 promoted KGN cell apoptosis.(A) Ectopic expression of SFRP1 promoted KGN cell apoptosis by flow cytometry.
(B) Ectopic expression of SFRP1 down-regulated the protein expression levels of
Bcl-2, and up-regulated Bax and cleaved caspase-3 in KGN cells by western blot.
*** p
In addition to the anti-proliferative and pro-apoptotic effects, the ectopic expression of SFRP1 also suppressed KGN cell migration (Fig. 4A). The protein expression of MMP2, MMP9 and Vimentin were decreased by pcDNA-SFRP1 compared to the control vector group (Fig. 4B), suggesting the anti-migratory effects of SFRP1 on the granulosa cells.
SFRP1 suppressed KGN cell migration.(A) Ectopic expression of SFRP1 suppressed KGN cell migration by transwell
assay.
(B) Ectopic expression of SFRP1 reduced the protein expression levels of MMP2,
MMP9 and Vimentin in KGN by western blot. * p
The protein expression of JNK was not significantly affected by SFRP1 over-expression compared to the control vector group (Fig. 5). However, transfection with pcDNA-SFRP1 in KGN cells decreased the protein expression of JNK phosphorylation (p-JNK) than the control vector group (Fig. 5), revealing that SFRP1 repressed the activation of JNK pathway to inhibit granulosa cell proliferation and migration.
SFRP1 repressed the activation of p-JNK in KGN cells.Ectopic expression of SFRP1 reduced the protein expression of p-JNK in KGN cells
by western blot. *** p
SFRPs directly bind to Frizzled receptors or Wnt ligands to inhibit Wnt signaling, and participate in tumor progression, including endometrial cancer and ovarian cancer [13]. Since Wnt activation was found to be related to the hallmarks of PCOS [8], SFRPs might be involved in the development of PCOS. Indeed, SFRP4 was significantly increased in the apoptotic granulosa cells, and was implicated in the premature differentiation of follicles during the development of PCOS [14]. SFRP5 level was related to the insulin and inflammatory markers in patients with PCOS [15]. However, to our best knowledge, the effects of SFRPs on PCOS have not been reported yet. Considering the fact that SFRP1 was reduced in the subcutaneous abdominal adipose stem cells isolated from patients with polycystic ovarian syndrome [12], this study is the first evidence demonstrating that SFRP1 suppressed granulosa cell proliferation and migration to attenuate PCOS.
A dramatically down-regulation of SFRP1 was identified in both of plasma samples from PCOS patients and KGN cells. Epigenetic alterations, such as DNA methylation of transcription factors, have been shown to be associated with the follicular development of granulosa cells, and involved in the development of PCOS [16]. SFRPs were often down-regulated in tumor tissues through hypermethylation of the promoters, and epigenetic modifying agents that repressed the methylation reversed the expression of SFRPs and further antagonized Wnt-driven tumorigenesis [13]. Hypermethylation of SFRP1 lead to impaired transcription and reactivation of SFRP1 attenuated pulmonary fibrosis in mice [17]. Therefore, the dynamic methylation of SFRP1 in PCOS should be investigated in the further research to provide potential therapeutic strategy for clinical implication of SFRP1 in PCOS. Drug-resistant cells, such as cancer stem cells, are responsible for the high rate of recurrence in epithelial ovarian cancer (Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives), and methylation of SFRP1 promoter is related to the primary cytogenetic resistance of chronic myeloid leukemia to imatinib mesylate (sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia). Therefore, SFRP1 might be a potential therapeutic target for the treatment of PCOS, and drug-resistant ovarian cancer.
Androgens are converted into estrogens in the granulosa cells, thus
participating in steroidogenesis [18]. Disturbance of steroidogenesis results in
hormonal abnormality, and is implicated in the pathogenesis of PCOS [19].
Regulation of granulosa cells is linked to the steroidogenic property of PCOS
[20]. Functional analysis in this study showed that ectopic expression of PCOS
reduced KGN cell viability and proliferation, while promoted cell apoptosis.
Previous study has shown that patients with PCOS demonstrated higher
proliferative rate and lower apoptotic rate in the granulosa cells than that in
the normal control [5]. The dysregulated granulosa cell proliferation resulted in
the prenatal folliculogenesis of PCOS patients [21]. Suppression of granulosa
cell proliferation has been regarded as a potential strategy for ovulation and
folliculogenesis in PCOS patients [22]. The anti-proliferative effect of SFRP1 on
KGN cells suggested that SFRP1 might be a potential therapeutic target for the
treatment of PCOS. Granulosa cell migration has been reported to essential for
the follicle development [23], and the aberrant migration of granulosa cells
regulated maturation of the oocyte and contributed to PCOS development [24].
Suppression of granulosa cell migration could repress PCOS progression [25]. In
this study, over-expression of SFRP1 reduced the protein expression of MMP2, MMP9
and Vimentin to suppress the KGN cell migration. Therefore, SFRP1 exerted
anti-migratory effect on granulosa cell to suppress PCOS progression.
Accumulating evidence has suggested that insulin-resistance is one of the most
important mechanism of PCOS pathogenesis [26], and insulin-sensitizer, such as
inositol isoforms, has been widely studied in the treatment of PCOS due to the
safety profile and effectiveness [27]. Since the mRNA expression of SFRP1 was
found to be negatively related to insulin resistance [28], and mice with
Sfrp1
JNK is involved in the non-canonical Wnt signaling pathway and associated with SFRPs-mediated tumor progression [13]. JNK pathway was activated in PCOS rats with elevated JNK phosphorylation level [30]. Inhibition of JNK reduced ovary fibrosis and suppressed inflammation to attenuate PCOS progression [31]. Moreover, JNK inactivation was also implicated in the suppression of granulosa cell proliferation and migration [32]. Phosphorylated JNK was enhanced in SFRP1 delete mice [33], and forced SFRP1 decreased JNK phosphorylation to protect cardiac myoblasts against doxorubicin-induced apoptosis [34]. This study indicated that ectopic expression of SFRP1 decreased JNK phosphorylation in KGN cells, revealing that JNK pathway was involved in SFRP1-mediated PCOS progression.
In conclusion, this study provided the first evidence showing that over-expression of SFRP1 suppressed granulosa cell proliferation and migration through inhibition of JNK pathway. Therefore, SFRP1 might be a novel therapeutic target for PCOS treatment. However, the in vivo effect of SFRP1 on PCOS should be further investigated for its clinical application.
SFRP1, Secreted frizzled-related protein 1; KGN, Immortalized human granulosa cells; CCK8, cell counting kit-8; PCOS, polycystic ovarian syndrome; DMEM, Dulbecco’s Modified Eagle Medium; qRT-PCR, Quantitative Reverse Transcription PCR; PVDF, Polyvinylidene Fluoride; SDS-PAGE, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
SZ designed the study, supervised the data collection, LX analyzed the data, interpreted the data, LYH prepared the manuscript for publication and reviewed the draft of the manuscript. All authors have read and approved the manuscript.
Ethical approval was obtained from the Ethics Committee of Hwa Mei Hospital, University of Chinese Academy of Sciences (Approval No. PJ-NBEY-KY-2020-182-01). Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.
Thanks to all the peer reviewers for their opinions and suggestions.
This work was supported by the Hwa Mei Research Fund of Hwa Mei Research Fund of Hwa Mei Hospital, University of Chinese Academy of Sciences (Grant No. 2019HMKY32).
The authors declare no conflict of interest.